 Home > Medical News > Latest Medical News > The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O drug by Kaixing Pharmaceutical was approved in China

The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O drug by Kaixing Pharmaceutical was approved in China

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

raw products

american cancer society locations

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Suzhou, October 11, 2021/PRNewswire/ - Development Pharmaceutical Co.

ALK-1 monoclonal antibody is a fully human monoclonal antibody that can inhibit ALK-1/TGF-β signal transduction and tumor angiogenesis.

The Phase II clinical trial (NCT03893695) of ALK-1 monoclonal antibody combined with Nivolumab for advanced HCC patients who progressed after treatment with rafenib or lenvatinib was first launched in Taiwan, China on May 7, 2019

On February 11, 2021, the Phase II clinical trial of ALK-1 monoclonal antibody combined with Nivolumab for the treatment of HCC was approved by the US FDA

Dr.

About Kaixing Pharmaceutical

Founded in 2009, Kapport Pharmaceuticals focuses on the development and industrialization of potential "best-in-class" and "first-in-class" innovative drugs, and is committed to becoming a leader in the research, development and commercialization of innovative therapies

Source: Kaifeng Pharmaceutical

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O-drug of Kaixing Pharmaceutical was approved in China

10-21

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O drug by Kaixing Pharmaceutical was approved in China

Related Articles

The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O-drug of Kaixing Pharmaceutical was approved in China